BRPI0820258B8 - composto, composições de vacina, e, uso de um composto - Google Patents

composto, composições de vacina, e, uso de um composto

Info

Publication number
BRPI0820258B8
BRPI0820258B8 BRPI0820258A BRPI0820258A BRPI0820258B8 BR PI0820258 B8 BRPI0820258 B8 BR PI0820258B8 BR PI0820258 A BRPI0820258 A BR PI0820258A BR PI0820258 A BRPI0820258 A BR PI0820258A BR PI0820258 B8 BRPI0820258 B8 BR PI0820258B8
Authority
BR
Brazil
Prior art keywords
compound
compounds
vaccine compositions
antigen
composition
Prior art date
Application number
BRPI0820258A
Other languages
English (en)
Inventor
Serra Vincent
Original Assignee
Abivax
Wittycel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Wittycel filed Critical Abivax
Publication of BRPI0820258A2 publication Critical patent/BRPI0820258A2/pt
Publication of BRPI0820258B1 publication Critical patent/BRPI0820258B1/pt
Publication of BRPI0820258B8 publication Critical patent/BRPI0820258B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

compostos, composições de vacina e farmacêutica, e, usos de um composto e de uma composição a presente invenção diz respeito aos compostos que consistem de glicolipídeos covalentemente ligados a um antígeno ou uma droga por intermédio de um ligador. os ditos compostos são capazes de induzir uma resposta imune mais forte do que uma composição que compreende glicolipídeos e antígeno separados. os ditos compostos também são capazes de alvejar droga para as células restritas cd1d.
BRPI0820258A 2007-11-07 2008-11-07 composto, composições de vacina, e, uso de um composto BRPI0820258B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99622607P 2007-11-07 2007-11-07
EP07291336.1 2007-11-07
US60/996226 2007-11-07
EP07291336A EP2058011A1 (en) 2007-11-07 2007-11-07 Nkt cell activating gycolipids covalently bound antigens and/or drug
PCT/EP2008/065179 WO2009060086A2 (en) 2007-11-07 2008-11-07 Increase of immune response and targeting by antigens and/or drug linkage

Publications (3)

Publication Number Publication Date
BRPI0820258A2 BRPI0820258A2 (pt) 2017-04-04
BRPI0820258B1 BRPI0820258B1 (pt) 2020-08-18
BRPI0820258B8 true BRPI0820258B8 (pt) 2021-05-25

Family

ID=39110389

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820258A BRPI0820258B8 (pt) 2007-11-07 2008-11-07 composto, composições de vacina, e, uso de um composto

Country Status (15)

Country Link
US (1) US8642565B2 (pt)
EP (2) EP2058011A1 (pt)
JP (1) JP5404639B2 (pt)
CN (1) CN101918033B (pt)
AU (1) AU2008324118B2 (pt)
BR (1) BRPI0820258B8 (pt)
CA (1) CA2705067C (pt)
DK (1) DK2231196T3 (pt)
ES (1) ES2584928T3 (pt)
IL (1) IL205583A (pt)
MX (1) MX2010005113A (pt)
PT (1) PT2231196T (pt)
RU (1) RU2548685C2 (pt)
WO (1) WO2009060086A2 (pt)
ZA (1) ZA201003286B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
CA2708246C (en) 2007-12-05 2016-05-24 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5933106B2 (ja) * 2012-03-19 2016-06-08 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー 炭水化物−糖脂質共役ワクチン
WO2014017928A1 (en) 2012-07-26 2014-01-30 Callaghan Innovation Research Limited Organic compounds
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
EP3925963A1 (en) * 2020-06-18 2021-12-22 Helmholtz-Zentrum für Infektionsforschung GmbH Phytosphingosine derivatives as adjuvants in immune stimulation
WO2022061096A1 (en) * 2020-09-17 2022-03-24 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide and a protein
MX2023010240A (es) 2021-03-01 2023-11-24 Deciduous Therapeutics Inc Compuestos para activar células t asesinas naturales invariantes y métodos de uso en la eliminación de células senescentes inflamatorias.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592453A (en) 1976-05-14 1981-07-08 Smith Kline French Lab Aminoalkyl esters of carbarimidothioic acid and compositions having immunosuppressant activity
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) 1992-07-16 1995-11-01 Kirin Brewery
KR100281264B1 (ko) 1992-10-22 2001-02-01 마나배 게이사꾸 신규한 스핀고당 지질 및 그의 사용
JP4020958B2 (ja) 1993-04-15 2007-12-12 キリンファーマ株式会社 新規スフィンゴ糖脂質およびその使用
RO117533B1 (ro) 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
DE69824301T2 (de) 1997-02-05 2005-06-02 Kirin Beer K.K. Glycosphingolipide enthaltende gefriergetrocknete zusammensetzung
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
DE69840528D1 (de) 1997-04-10 2009-03-19 Kyowa Hakko Kirin Co Ltd NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
JP2001527046A (ja) 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
CA2320117A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1277472A4 (en) 2000-04-28 2005-06-08 Orient Cancer Therapy Co Ltd REMEDIES AGAINST CANCER
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
JP2005500336A (ja) 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
CA2469406A1 (en) 2001-11-06 2003-05-15 Orient Cancer Therapy Co., Ltd. Anticancer compositions
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
WO2005102049A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR101377116B1 (ko) 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
EP1786439B1 (en) 2004-09-03 2010-04-14 The University Of Chicago Methods of activating nkt cells
EP1833489A4 (en) 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
AU2006211485B2 (en) 2005-01-28 2011-04-14 Brigham Young University Bacterial glycolipid activation of CD1d-restricted NKT cells
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
PT2056842E (pt) * 2006-04-07 2013-01-24 Univ Chicago Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
JP5564672B2 (ja) 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
CA2708246C (en) * 2007-12-05 2016-05-24 Wittycell Compositions for and methods of enhancing the immune response to antigens

Also Published As

Publication number Publication date
CN101918033A (zh) 2010-12-15
IL205583A0 (en) 2010-11-30
CN101918033B (zh) 2012-12-05
WO2009060086A3 (en) 2009-12-10
US8642565B2 (en) 2014-02-04
WO2009060086A2 (en) 2009-05-14
EP2231196A2 (en) 2010-09-29
ZA201003286B (en) 2011-03-30
JP2011503034A (ja) 2011-01-27
AU2008324118A1 (en) 2009-05-14
RU2010122946A (ru) 2011-12-20
CA2705067A1 (en) 2009-05-14
BRPI0820258B1 (pt) 2020-08-18
AU2008324118B2 (en) 2013-05-16
CA2705067C (en) 2016-08-16
PT2231196T (pt) 2016-08-23
ES2584928T3 (es) 2016-09-30
DK2231196T3 (en) 2016-08-22
US20100330111A1 (en) 2010-12-30
MX2010005113A (es) 2010-10-07
IL205583A (en) 2014-05-28
JP5404639B2 (ja) 2014-02-05
EP2058011A1 (en) 2009-05-13
RU2548685C2 (ru) 2015-04-20
EP2231196B1 (en) 2016-05-25
BRPI0820258A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
AR118559A2 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de las células t
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0910388A2 (pt) agentes terapêutico antivirais.
ECSP11011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
BR122016002916B8 (pt) diacorpo, molécula de ácido nucleico, composição farmacêutica e usos do diacorpo
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112013019628A2 (pt) conjugados de polímero-carboidrato-lipídeo
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
CR10555A (es) Vacunas para malaria
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
BR112012014624A8 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
MX2010005113A (es) Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco.
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABIVAX (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07H 15/06 (2006.01), A61K 39/385 (2006.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF